{"id":"W4281695484","doi":"10.1200/jco.2022.40.16_suppl.tps9159","title":"AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with <i>RET</i> fusion–positive advanced/metastatic NSCLC.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Pemetrexed; Internal medicine; Lung cancer; Oncology; Crizotinib; Response Evaluation Criteria in Solid Tumors; Population; Gemcitabine; Adverse effect; Phases of clinical research; Clinical trial; Cancer; Chemotherapy; Immunotherapy; Malignant pleural effusion","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001925359,0.001642419,0.001731058,0.0005248532,0.0004268822,0.001174305,0.0009274853,0.001486936,0.00807221],"category_scores_gemma":[0.0008481317,0.0006504615,0.002033767,0.0004408353,0.0006216173,0.001085679,0.0003679198,0.004202487,0.001722611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001321189,"about_ca_system_score_gemma":0.002408801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001542926,"about_ca_topic_score_gemma":0.00591798,"domain_scores_codex":[0.9997092,0.0001242115,0.00001191559,0.00005029279,0.00004107891,0.00006328127],"domain_scores_gemma":[0.9994826,0.00007496908,0.0001235377,0.00003431601,0.00004063908,0.0002438777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6830199,0.07993143,0.009581203,0.002560894,0.002793046,0.0005811055,0.000420723,0.003682202,0.04023972,0.0008419064,0.02805509,0.1482929],"study_design_scores_gemma":[0.7820699,0.1951248,0.01071216,0.00009879444,0.0007076052,0.0005334878,0.00005757872,0.001126762,0.002030678,0.000340658,0.007158608,0.00003912234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.965241,0.006157734,0.001069365,0.002023062,0.0005038258,0.008579276,0.00832207,0.0005078195,0.007595799],"genre_scores_gemma":[0.9497627,0.006363207,0.004488423,0.004521951,0.0003975057,0.01032817,0.01251601,0.0001337412,0.01148825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00807221,"threshold_uncertainty_score":0.02700418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0640521458669212,"score_gpt":0.4968587128532268,"score_spread":0.4328065669863056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}